The Drug Information Center Arthritis Project: Providing Patients with Interactive and Reliable Arthritis Internet Educa
- PDF / 14,174,804 Bytes
- 11 Pages / 648 x 864 pts Page_size
- 12 Downloads / 172 Views
Nicole 7. Ansani, PharmD University of Pittsburgh, School of Pharmacy Pfizer, Inc. Bethany A. FedrtesHenderson, PhoraD Robert 1. Weber, MS, RPh Randall Smith, PhD Jennine Dean, RPh University ofpittsburgh, School of Pharmacy. Pittsburgh, Pennsylvania
Molly Vogt, PhD Kenneth Gold, MD C. Kent Kwoh, M D Thaddeus Osiol, MD Terence W. Starz, MD University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Key Words Arthritis; Osteoarthritis; Rheumatoid arthritis; Internet; Web site; Education; Patient education; Pharmacist; Pharmacy Drug information; Medication information Correspondence Address Nicole T.Ansani, PharmD, 114 Alpine Circle, Pittsburgh, PA 15215 (e-mail: [email protected]). At the time ofwriting, Dr. Ansani was Associate Director, Drug Information, University of Pittsburgh Medical Center, and Assistant Professor, Department of Pharmacy and Therapeutics. University ofPittsburgh School of Pharmacy She currently is Clinical Education Consultant. Pfizer, Inc. The authors would like to acknowledge the administrative support of Shari Squeglia. This project was funded by a grant from the Drug Information Association.
39
The Drug Information Center Arthritis Project: Providing Patients With Interactive and Reliable Arthritis Internet Education The objective of the Drug Information Center Arthritis Project was to create and assess the value of a patient-focused intemctive arthritis education pmgmm. A multidisciplinary team developed three content areas: an interactive ask-a-pharmacist component with a satisfaction suwey: health assessment tods (SF-2ITM, osteoarthritis [OA] lmpact SuweyTM,and rheumatoid arthritis [RA] Impact Suwey?; and disease and drug information. Results: There were 1,800 patients with OA, RA, or both from a collaboratingrheumatdogy pmctice who were invited to use a personalized, interactive, secured Internet arthritis Web site. During a 6-week pilot, 56 patients accessed the site for a total of 128 visits. Patient satis-
INTRODUCTION Arthritis is the leading cause of disability in the United States; over 21 million Americans are diagnosed with osteoarthritis (OA), and 2 million Americans are diagnosed with rheumatoid arthritis (RA) (1). As the American population ages, it is predicted that by the year 2020 the number of patients afflicted with arthritis will increase to 60 million (1). Although OA is the most common type of arthritis and often leads to significant disability and decreased quality of life, both OA and RA are chronic arthridites with variable course and progression of disease (2,3). Over the past decade, important advances in the treatment of both RA and OA have become available. These advances include the introduction of biologics to the market for the treatment of RA and an inversion of the traditional RA treatment pyramid by which patients are starting disease-modifying antirheumatic drug therapy or biologic agents earlier, with combination therapy becoming more commonplace. Although there are no agents available to mitigate
faction scores showed that 83% of pa
Data Loading...
